Skin lesions occur frequently in patients taking anti-tumor necrosis factor (TNF) antagonists for inflammatory bowel disease (IBD), but discontinuation of therapy is usually not required.
Tissue Regenix Ltd, the regenerative medical device company, is pleased to announce that two patients have received the first OrthoPure™ XT decellularised tendons using Tissue Regenix...
Effimune has announced, the publication in leading scientific journals of three different studies confirming the efficacy of FR104 in new preclinical models, and suggesting that it could be a...
In a recent study published in the SAGE open access journal Scars, Burns & Healing, in affiliation with The Katie Piper Foundation, leading researchers from the St.